CAR细胞疗法在T细胞-急性淋巴细胞白血病应用的新进展

New Advances in the Application of CAR Cell Therapy in T Cell-acute Lymphoblastic Leukemia

嵌合抗原受体(chimeric antigen receptors,CAR)细胞疗法已广泛用于白血病、淋巴瘤的治疗,CD19和CD22靶向CAR-T已在复发、难治性急性B淋巴细胞白血病(RR-B-ALL)等血液系统疾病的治疗上取得了显著疗效,而在T细胞肿瘤治疗上进展缓慢。介绍了目前国内外利用CAR细胞技术与CRISPR/Cas9基因编码技术,设计了T-ALL相关的CAR细胞免疫疗法并进行了CAR细胞免疫疗法在T-ALL治疗上的初步探索。

Currently,cell therapy of Chimeric antigen receptors(CAR)has been widely used in the treatment of leukemia and lymphoma.CD19 and CD22 targeting CAR-T have shown significant efficacy in the treatment of recurrent and refractory acute B-lymphoblastic leukemia(RR-B-ALL)and other hematologic diseases.However,the progress is slow in the treatment of T-lineage tumors.This review introduces the current domestic and international use of CAR cell technology and CRISPR/Cas9 gene coding technology to design T-ALL CAR cell and the preliminary exploration of CAR cell immunotherapy in the treatment of T-lineage acute lymphoblastic leukaemia.